Tumour suppressor TET2 safeguards enhancers from aberrant DNA methylation and epigenetic reprogramming in ER&#945;-positive breast cancer cells.

Lyu, Ruitu; Zhu, Xuguo; Shen, Yinghui; Xiong, Lijun; Liu, Lu; Liu, Hang; Wu, Feizhen; Argueta, Christian; Tan, Li

Tumour suppressor TET2 safeguards enhancers from aberrant DNA methylation and epigenetic reprogramming in ERα-positive breast cancer cells.

Lyu, Ruitu; Zhu, Xuguo; Shen, Yinghui; Xiong, Lijun; Liu, Lu; Liu, Hang; Wu, Feizhen; Argueta, Christian; Tan, Li.

Afiliação

Lyu R; Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, and Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Zhu X; Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, and Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Shen Y; Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, and Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Xiong L; Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, and Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Liu L; Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, and Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Liu H; Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, and Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Wu F; Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, and Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Argueta C; Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Tan L; Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, and Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.

Epigenetics ; 17(10): 1180-1194, 2022 10.

Article em En | MEDLINE | ID: mdl-34689714

Assuntos

Neoplasias da Mama; Dioxigenases; Biomarcadores Tumorais/metabolismo; Neoplasias da Mama/genética; Neoplasias da Mama/patologia; DNA/metabolismo; Metilação de DNA; Proteínas de Ligação a DNA/genética; Proteínas de Ligação a DNA/metabolismo; Dioxigenases/metabolismo; Elementos Facilitadores Genéticos; Epigênese Genética; Estradiol; Receptor alfa de Estrogênio/genética; Receptor alfa de Estrogênio/metabolismo; Estrogênios; Feminino; Humanos; Metiltransferases/genética; Proteínas Proto-Oncogênicas/genética; Proteínas Proto-Oncogênicas/metabolismo; RNA Mensageiro/metabolismo

Palavras-chave

Breast cancer; ERα; TET2; enhancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Dioxigenases Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Epigenetics Assunto da revista: GENETICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google